Nanishi, Etsuro <br/><br/>
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.  [electronic resource] 

 -  Journal of the American Heart Association  Jul 2017 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2047-9980 
<br/><br/><label>Standard No.: </label>10.1161/JAHA.116.005370  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Anti-Bacterial Agents--adverse effects<br/>Bacteriological Techniques<br/>Biofilms--drug effects<br/>Child<br/>Child, Preschool<br/>Clarithromycin--adverse effects<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Immunity, Innate--drug effects<br/>Immunoglobulins, Intravenous--adverse effects<br/>Immunologic Factors--adverse effects<br/>Infant<br/>Japan<br/>Length of Stay<br/>Male<br/>Mucocutaneous Lymph Node Syndrome--diagnosis<br/>Multiplex Polymerase Chain Reaction<br/>Recurrence<br/>Time Factors<br/>Treatment Outcome